BioCentury | Apr 15, 2020
Finance

April 14 Quick Takes: Digital Dx play Perspectum raises $36M; plus Akeso’s IPO terms, 54gene, i2O and Immunovant

...Capital, V8 Capital, Ingressive Capital and Aera VC joined existing investors Y Combinator, Better Ventures, Fifty Years...
BioCentury | Dec 8, 2008
Regulation

Seek, but not find

In voting to recommend approval of Uloric febuxostat to treat chronic gout, FDA 's Arthritis Advisory Committee concluded that its benefits trumped an ambiguous cardiovascular safety signal. The committee voted 12-0 with one abstention on...
Items per page:
1 - 2 of 2
BioCentury | Apr 15, 2020
Finance

April 14 Quick Takes: Digital Dx play Perspectum raises $36M; plus Akeso’s IPO terms, 54gene, i2O and Immunovant

...Capital, V8 Capital, Ingressive Capital and Aera VC joined existing investors Y Combinator, Better Ventures, Fifty Years...
BioCentury | Dec 8, 2008
Regulation

Seek, but not find

In voting to recommend approval of Uloric febuxostat to treat chronic gout, FDA 's Arthritis Advisory Committee concluded that its benefits trumped an ambiguous cardiovascular safety signal. The committee voted 12-0 with one abstention on...
Items per page:
1 - 2 of 2